EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients

Nilesh Kumta iD, Aaron J Heffernan iD, Menino Osbert Cotta iD, Xin Liu, Suzanne Parker iD, Steven Wallis, Amelia Livermore, Therese Starr, Wai Tat Wong, Gavin M Joynt, Jeffrey Lipman, Jason A Roberts iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00601-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Nilesh Kumta und 11 weiteren Autor:innen. Beteiligte Einrichtung: The University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Piperacillin, Tazobactam Drug Combination, Anti-Bacterial Agents, Cerebral Ventriculitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intensive Care Foundation (ICF), Royal Brisbane and Women's Hospital Foundation (RBWH Foundation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ventriculitis in neurocritical care patients leads to significant morbidity and mortality. Antibiotic dose optimization targeting pharmacokinetic/pharmacodynamic (PK/PD) exposures associated with improved bacterial killing may improve therapeutic outcomes. We sought to develop and apply a population PK model in infected critically ill patients to determine optimal piperacillin-tazobactam (PTZ) dosing regimens to achieve target cerebrospinal fluid (CSF) exposures. Neurosurgical patients with external ventricular drains and receiving PTZ treatment were recruited and had plasma and CSF samples collected and assayed. A population PK model was developed using plasma and CSF piperacillin and tazobactam concentrations. Eight patients were recruited. Median age was 59 years, median weight was 70 kg, and five patients were female. The median creatinine clearance was 84 mL/min/1.73 m 2 (range 52–163). Substantial inter-individual PK variability was apparent, particularly in CSF. Piperacillin penetration into CSF had a median of 3.73% (range 0.73%–7.66%), and tazobactam CSF penetration was not predictable. Dosing recommendations to optimize CSF exposures for the treatment of ventriculitis were not possible due to substantial PK variability and very low drug penetration. High plasma PTZ exposures may not translate to effective exposures in CSF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Piperacillin, Tazobactam Drug CombinationAnti-Bacterial AgentsCerebral VentriculitisHumansFemaleMiddle AgedCritical IllnessMaleAgedPiperacillinAdultTazobactamMicrobial Sensitivity Tests

Stichwörter der Autor:innen

antibioticscerebrospinal fluidcritical illnesspharmacokinetic/pharmacodynamicpiperacillin-tazobactamventriculitisventriculostomy-associated infection

Substanzen

Piperacillin, Tazobactam Drug CombinationAnti-Bacterial AgentsPiperacillinTazobactam

Autor:innen und Institutionen

  • The University of Queensland Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, Brisbane, Queensland, Australia.
  • School of Medicine, Griffith University, Southport, Queensland, Australia.
  • Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Herston, Brisbane, Queensland, Australia.
  • Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong, China.
  • Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nimes University Hospital, University of Montpellier, Nimes, France.
  • Jamieson Trauma Institute, Royal Brisbane and Women's Hospital, Herston, Brisbane, Queensland, Australia.

ORCID-Profile: Nilesh Kumta, Aaron J Heffernan, Menino Osbert Cotta, Suzanne Parker, Jason A Roberts

Förderung

  • Intensive Care Foundation (ICF)
  • Royal Brisbane and Women's Hospital Foundation (RBWH Foundation)

Zitieren

APA

Kumta, N., Heffernan, A. J., Cotta, M. O., Liu, X., Parker, S., Wallis, S., Livermore, A., Starr, T., Wong, W. T., Joynt, G. M., Lipman, J., & Roberts, J. A. (2025). Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00601-24

Vancouver

Kumta N, Heffernan AJ, Cotta MO, Liu X, Parker S, Wallis S, et al. Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00601-24

BibTeX
@article{Kumta2025,
  author = {Kumta, Nilesh and Heffernan, Aaron J and Cotta, Menino Osbert and Liu, Xin and Parker, Suzanne and Wallis, Steven and Livermore, Amelia and Starr, Therese and Wong, Wai Tat and Joynt, Gavin M and Lipman, Jeffrey and Roberts, Jason A},
  title = {Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00601-24}
}
Kostenlos starten →